You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR IMATINIB MESYLATE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for IMATINIB MESYLATE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Medical Research Council	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	National Cancer Institute (NCI)	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Eastern Cooperative Oncology Group	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00004932 ↗	STI571 in Treating Patients With Recurrent Leukemia	Completed	National Cancer Institute (NCI)	Phase 1	2002-01-01	RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent leukemia.
NCT00004932 ↗	STI571 in Treating Patients With Recurrent Leukemia	Completed	Children's Oncology Group	Phase 1	2002-01-01	RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent leukemia.
NCT00006052 ↗	STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia	Completed	Novartis	Phase 2	2000-06-01	RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have accelerated phase chronic myelogenous leukemia.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for IMATINIB MESYLATE

Condition Name

Chart
Table

Condition Name for IMATINIB MESYLATE
Intervention	Trials
Leukemia	58
Gastrointestinal Stromal Tumor	23
Chronic Myeloid Leukemia	18
Gastrointestinal Stromal Tumors	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for IMATINIB MESYLATE
Intervention	Trials
Leukemia	137
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	105
Leukemia, Myeloid	101
Gastrointestinal Stromal Tumors	54
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for IMATINIB MESYLATE

Trials by Country

Map
Table

Trials by Country for IMATINIB MESYLATE
Location	Trials
United States	962
Canada	73
Australia	53
Italy	48
United Kingdom	47
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for IMATINIB MESYLATE
Location	Trials
Texas	82
California	66
New York	55
Pennsylvania	46
Massachusetts	45
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for IMATINIB MESYLATE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for IMATINIB MESYLATE
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	34
Phase 2/Phase 3	5
[disabled in preview]	305
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for IMATINIB MESYLATE
Clinical Trial Phase	Trials
Completed	235
Terminated	58
Unknown status	25
[disabled in preview]	38
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for IMATINIB MESYLATE

Sponsor Name

Chart
Table

Sponsor Name for IMATINIB MESYLATE
Sponsor	Trials
National Cancer Institute (NCI)	111
Novartis Pharmaceuticals	52
Novartis	44
[disabled in preview]	64
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for IMATINIB MESYLATE
Sponsor	Trials
Other	340
Industry	174
NIH	116
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.